MedTrace Logo

Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

NCT04252833 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-06-12

No results posted yet for this study

Summary

This open-label study will be conducted to assess the bioavailability and PK of oral single doses of CT-044 following administration with and without food and to evaluate the safety and tolerability of CT-044 when given with and without food.

Conditions

Interventions

DRUG

CT-044

CT-044 HCl is a reactive species decomposition accelerant

Sponsors & Collaborators

  • CerSci Therapeutics

    collaborator UNKNOWN

  • Lotus Clinical Research, LLC

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-18
Primary Completion
2020-03-16
Completion
2020-03-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04252833 on ClinicalTrials.gov